Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K.

N Engl J Med. 1997 Sep 25;337(13):874-80.

2.

Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.

Matsumoto K, Ogawa N, Nerome K, Numazaki Y, Kawakami Y, Shirato K, Arakawa M, Kudoh S, Shimokata K, Nakajima S, Yamakido M, Kashiwagi S, Nagatake T.

Antivir Ther. 1999;4(2):61-8.

PMID:
10682150
3.
4.

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.

Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ; Zanamivir Family Study Group.

N Engl J Med. 2000 Nov 2;343(18):1282-9.

5.

Effect of zanamivir on duration and resolution of influenza symptoms.

Monto AS, Moult AB, Sharp SJ.

Clin Ther. 2000 Nov;22(11):1294-305.

PMID:
11117654
6.

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O.

Pediatr Infect Dis J. 2000 May;19(5):410-7.

PMID:
10819336
7.

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.

Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, Elliott M, Keene ON, Man CY.

J Infect Dis. 1999 Aug;180(2):254-61.

PMID:
10395837
8.

Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors.

Höffken G, Gillissen A.

Med Microbiol Immunol. 2002 Dec;191(3-4):169-73. Epub 2002 Sep 11. Review.

PMID:
12458354
9.

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials.

Lalezari J, Campion K, Keene O, Silagy C.

Arch Intern Med. 2001 Jan 22;161(2):212-7.

PMID:
11176734
10.

Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

[No authors listed]

Lancet. 1998 Dec 12;352(9144):1877-81. Erratum in: Lancet 1999 Feb 6;353(9151):504. Lancet 1999 Mar 27;353(9158):1104.

PMID:
9863784
11.

Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.

Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG.

Arch Intern Med. 2000 Nov 27;160(21):3234-40.

PMID:
11088083
12.

Spotlight on zanamivir in influenza.

Cheer SM, Wagstaff AJ.

Am J Respir Med. 2002;1(2):147-52. Review.

PMID:
14720068
13.

Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults.

Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S.

J Infect Dis. 2000 Apr;181(4):1471-4. Epub 2000 Apr 13.

PMID:
10762579
14.

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis.

Monto AS, Webster A, Keene O.

J Antimicrob Chemother. 1999 Nov;44 Suppl B:23-9.

PMID:
10877459
15.

Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection.

Calfee DP, Peng AW, Hussey EK, Lobo M, Hayden FG.

Antivir Ther. 1999;4(3):143-9.

PMID:
12731753
16.

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.

Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK.

JAMA. 1996 Jan 24-31;275(4):295-9.

PMID:
8544269
17.

Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.

Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A, Syndergaard T, Kim CU.

Antiviral Res. 1998 Feb;37(2):107-20.

PMID:
9588843
18.

Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.

Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG.

Antimicrob Agents Chemother. 1999 Jul;43(7):1616-20.

19.

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.

LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.

Clin Ther. 2007 Aug;29(8):1579-90; discussion 1577-8.

PMID:
17919541

Supplemental Content

Support Center